CCDC148 Inhibitors
Chemical inhibitors of CCDC148 exploit various molecular pathways to reduce the protein's activity. Staurosporine, a broad-spectrum protein kinase inhibitor, can impede the phosphorylation of numerous proteins, including CCDC148. By inhibiting the kinases that phosphorylate CCDC148, Staurosporine can decrease the protein's activity. Similarly, Palbociclib, by targeting CDK4 and CDK6, can disrupt cell cycle-regulated processes that involve CCDC148, leading to its inactivity. Trichostatin A, which inhibits histone deacetylases, can also affect CCDC148 if its function is regulated by acetylation; the hyperacetylated state maintained by Trichostatin A can suppress the protein's function. Another inhibitor, MG-132, targets the proteasome, leading to the build-up of ubiquitinated proteins, which may include CCDC148. This build-up can impede CCDC148's function due to the accumulation of malformed or aggregated proteins.
Further, LY294002, by inhibiting PI3K, can shut down signaling pathways that involve CCDC148, leading to a decrease in the protein's activity. Rapamycin, an mTOR inhibitor, can similarly affect CCDC148 if it is involved in mTOR-related cellular processes. The inhibition of mTOR can suppress CCDC148's role in cell growth and metabolism. In the context of MAP kinase pathways, SB203580 and PD98059 can attenuate CCDC148's activity by inhibiting p38 MAPK and MEK, respectively. SB203580 directly inhibits p38 MAPK, which may regulate CCDC148, while PD98059 blocks MEK, thereby disrupting the MAPK/ERK pathway which can regulate CCDC148's function. Additionally, PP2, an Src family kinase inhibitor, and Gefitinib, an EGFR tyrosine kinase inhibitor, can reduce the activity of CCDC148 if it is regulated by Src family kinase or EGFR signaling. Lastly, Y-27632, a ROCK inhibitor, can decrease CCDC148's activity if it is involved in pathways governed by Rho-associated kinases, by inhibiting these kinases and the pathways they control.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. CCDC148 may be regulated by phosphorylation through various kinases; hence, staurosporine can inhibit CCDC148 activity by inhibiting the kinases responsible for its phosphorylation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. CCDC148's function may be regulated by the cell cycle, and inhibition of CDKs by palbociclib can disrupt this regulation, leading to the inhibition of CCDC148's activity. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A inhibits histone deacetylases (HDACs). While it is primarily known to affect gene expression, it can also alter the acetylation status of non-histone proteins. If CCDC148 is subject to acetylation, Trichostatin A could inhibit its function by maintaining its hyperacetylated state, which might inhibit its activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor. By inhibiting the proteasome, MG-132 can increase the levels of ubiquitinated proteins, potentially including CCDC148 if it undergoes ubiquitination, which could inhibit its normal function due to accumulation of improperly folded or aggregated proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, LY294002 can inhibit downstream signaling pathways that may involve CCDC148, thereby inhibiting the protein's function in these pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. As CCDC148 might interact with mTOR signaling pathways, inhibition of mTOR by rapamycin could lead to a decrease in CCDC148 activity related to cell growth and metabolism. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK can lead to reduced activity of proteins like CCDC148 that are regulated by the p38 MAPK pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinases inhibitor. If CCDC148 is regulated by Src family kinase signaling, PP2 can inhibit this regulation, thereby inhibiting the function of CCDC148. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor. If CCDC148 plays a role in mitosis where Aurora kinases are key regulators, inhibition by ZM-447439 could lead to inhibition of CCDC148 activity during cell division. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, which could inhibit the MAPK/ERK pathway. As such, if CCDC148 activity is regulated by this pathway, PD98059 could inhibit the protein's function. | ||||||